IOB - Delayed Quote EUR

UCB SA (0NZT.IL)

Compare
181.95 -1.40 (-0.76%)
At close: 5:36 PM GMT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 0NZT.IL

Recent News: 0NZT.IL

View More
UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
UCB Announces a Head-to-Head Study Evaluating BIMZELX? (bimekizumab) versus SKYRIZI? (risankizumab) in Active Psoriatic Arthritis

UCB Announces a Head-to-Head Study Evaluating BIMZELX? (bimekizumab) versus SKYRIZI? (risankizumab) in Active Psoriatic Arthritis
UCB Announces Late-Breaking Two-Year Data for BIMZELX? (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces Late-Breaking Two-Year Data for BIMZELX? (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
UCB Presents New 4-year Data for BIMZELX? (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

UCB Presents New 4-year Data for BIMZELX? (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial

Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
UCB Announces U.S. FDA Approvals for BIMZELX? (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

UCB Announces U.S. FDA Approvals for BIMZELX? (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB

Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
Belgium stocks higher at close of trade; BEL 20 up 0.33%

Belgium stocks higher at close of trade; BEL 20 up 0.33%

Belgium stocks higher at close of trade; BEL 20 up 0.73%
Best Momentum Stock to Buy for August 19th

Best Momentum Stock to Buy for August 19th
View More

Related Tickers